ARS Pharmaceuticals, Inc. SPRY Accrued Progress Collections and Price Adjustments
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s accrued progress collections and price adjustments.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s accrued progress collections and price adjustments?
- ARS Pharmaceuticals, Inc. (SPRY) reported accrued progress collections and price adjustments of $978K in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s accrued progress collections and price adjustments changed year-over-year?
- ARS Pharmaceuticals, Inc.'s accrued progress collections and price adjustments decreased by 27.0% year-over-year, from $1.34M to $978K.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s accrued progress collections and price adjustments?
- Over 4 years (2021 to 2025), ARS Pharmaceuticals, Inc.'s accrued progress collections and price adjustments has grown at a -21.6% compound annual growth rate (CAGR), from $3M to $1.13M.